Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REC611C301 phase 3 placebo-controlled trial of ReCOV for prevention of COVID-19
PACTR202111689978502Phase 3Not yet recruiting
- Sponsor
- Recbio
- Start
- Jan 2022
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ReCOV in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Recbio. Primary endpoints: RT-PCR confirmed symptomatic COVID-19 after full vaccination in Period 1/controlled efficacy period, Adverse events through 28 days after dose 2 in Period 2 and 1 more. Planned start Jan 2022; status: not yet recruiting.
02
Drugs
ReCOV
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on PACTR202111689978502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202111689978502.